Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1970 Feb;38(2):416–432. doi: 10.1111/j.1476-5381.1970.tb08529.x

A comparison of the cardiovascular actions of AQ 110 with those of isoprenaline and salbutamol

F Fogelman, H F Grundy
PMCID: PMC1702809  PMID: 4392103

Abstract

1. AQ 110 is a β-adrenoceptor agonist which, like isoprenaline and salbutamol, acts directly on the receptors.

2. Compared with isoprenaline, AQ 110 has relatively stronger actions on bronchial and vascular smooth muscle (β2-adrenoceptors) than stimulant effects on heart muscle (β1-adrenoceptors). The β2-selectivity of AQ 110 is, however, much less than that of salbutamol, mainly due to the weak cardiac actions of the latter.

3. At doses which were equipotent in decreasing the bronchoconstrictor effect produced by a standard dose of 5-hydroxytryptamine, AQ 110 had marginally less hypotensive action than salbutamol and considerably less than isoprenaline.

4. Although AQ 110, unlike salbutamol, possesses a catechol group it was found not to be a substrate for catechol-O-methyl transferase and this is considered to account for its significantly prolonged action, compared with isoprenaline, in vivo.

Full text

PDF
416

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burba J. V., Murnaghan M. F. Catechol-o-methyl transferase inhibition and potentiation of epinephrine responses by desmethylpapavernine. Biochem Pharmacol. 1965 May;14(5):823–829. doi: 10.1016/0006-2952(65)90101-2. [DOI] [PubMed] [Google Scholar]
  2. Cullum V. A., Farmer J. B., Jack D., Levy G. P. Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br J Pharmacol. 1969 Jan;35(1):141–151. doi: 10.1111/j.1476-5381.1969.tb07975.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. De la Lande I. S., Rand M. J. A simple isolated nerve-blood vessel preparation. Aust J Exp Biol Med Sci. 1965 Oct;43(5):639–656. doi: 10.1038/icb.1965.48. [DOI] [PubMed] [Google Scholar]
  4. Dungan K. W., Cho Y. W., Gomoll A. W., Aviado D. M., Lish P. M. Pharmacologic potency and selectivity of a new bronchodilator agent: soterenol (MJ 1992). J Pharmacol Exp Ther. 1968 Dec;164(2):290–301. [PubMed] [Google Scholar]
  5. Iwasawa Y., Kiyomoto A. Studies on tetrahydroisoquinolines (THI). I. Bronchodilator activity and structure-activity relationship. Jpn J Pharmacol. 1967 Jun;17(2):143–152. doi: 10.1254/jjp.17.143. [DOI] [PubMed] [Google Scholar]
  6. LANDS A. M., BROWN T. G., Jr A COMPARISON OF THE CARDIAC STIMULATING AND BRONCHODILATOR ACTIONS OF SELECTED SYMPATHOMIMETIC AMINES. Proc Soc Exp Biol Med. 1964 Jun;116:331–333. doi: 10.3181/00379727-116-29239. [DOI] [PubMed] [Google Scholar]
  7. Lands A. M., Arnold A., McAuliff J. P., Luduena F. P., Brown T. G., Jr Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967 May 6;214(5088):597–598. doi: 10.1038/214597a0. [DOI] [PubMed] [Google Scholar]
  8. SUTTER M. C. THE PHARMACOLOGY OF ISOLATED VEINS. Br J Pharmacol Chemother. 1965 Jun;24:742–751. doi: 10.1111/j.1476-5381.1965.tb01630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sato M., Yamaguchi I., Kiyomoto A. Studies on tetradhydroisoquinolines (THI). II. Pharmacological action on the cardiovascular system. Jpn J Pharmacol. 1967 Jun;17(2):153–163. doi: 10.1254/jjp.17.153. [DOI] [PubMed] [Google Scholar]
  10. van ROSSUM J. The relation between chemical structure and biological activity. Discussion of possibilities, pitfalls and limitations. J Pharm Pharmacol. 1963 May;15:285–316. doi: 10.1111/j.2042-7158.1963.tb12787.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES